Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LP

Woodline Partners LP raised its position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 53.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,089,461 shares of the company's stock after purchasing an additional 379,630 shares during the period. Woodline Partners LP owned about 1.16% of Scholar Rock worth $47,087,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Scholar Rock by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after acquiring an additional 379 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after acquiring an additional 620 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares during the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Scholar Rock by 16.9% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,109 shares of the company's stock valued at $350,000 after acquiring an additional 1,170 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $42.67.

Insiders Place Their Bets

In other news, insider Tracey Sacco sold 5,000 shares of Scholar Rock stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total value of $164,150.00. Following the transaction, the insider now directly owns 71,750 shares of the company's stock, valued at $2,355,552.50. The trade was a 6.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the completion of the transaction, the chief financial officer now directly owns 111,345 shares in the company, valued at $3,966,108.90. This represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 223,308 shares of company stock valued at $8,044,512. Insiders own 13.30% of the company's stock.

Scholar Rock Stock Down 1.3%

Shares of NASDAQ:SRRK opened at $30.16 on Tuesday. The stock's 50-day moving average price is $31.07 and its two-hundred day moving average price is $35.98. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -12.83 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period in the previous year, the business earned ($0.59) earnings per share. On average, research analysts forecast that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.